Physician profile
Antonios Paras
NPI 1497722854
$9,643.86
in general payments reported to CMS, 2019-2025
50 companies · $1,583 in 2025
The $1,583 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,122 · 2020: $938 · 2021: $1,324 · 2022: $1,339 · 2023: $1,630 · 2024: $1,708 · 2025: $1,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,920.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,365.29 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,008.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $904.97 | 2021-2025 | |
| Lilly USA, LLC | $658.56 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $579.55 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $470.03 | 2019-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $419.40 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $392.21 | 2019-2024 | Verquvo, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $373.07 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $298.28 | 2019-2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $274.58 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $274.13 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Astellas Pharma US INC | $218.79 | 2019-2025 | Veozah, Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $167.15 | 2021-2023 | Airduo Digihaler |
| Novartis Pharmaceuticals Corporation | $165.08 | 2019-2023 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonios Paras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.